ATE482946T1 - Chinazolinderivate als angiogenesehemmer und zwischenprodukte dafür - Google Patents

Chinazolinderivate als angiogenesehemmer und zwischenprodukte dafür

Info

Publication number
ATE482946T1
ATE482946T1 AT05004285T AT05004285T ATE482946T1 AT E482946 T1 ATE482946 T1 AT E482946T1 AT 05004285 T AT05004285 T AT 05004285T AT 05004285 T AT05004285 T AT 05004285T AT E482946 T1 ATE482946 T1 AT E482946T1
Authority
AT
Austria
Prior art keywords
alkyl
alkylsulphonyl
amino
compounds
formula
Prior art date
Application number
AT05004285T
Other languages
English (en)
Inventor
Laurent Francois Andre Hennequin
Patrick Ple
Elaine Sophie Stokes
Darren Mckerrecher
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE482946T1 publication Critical patent/ATE482946T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT05004285T 1999-02-10 2000-02-08 Chinazolinderivate als angiogenesehemmer und zwischenprodukte dafür ATE482946T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99400305 1999-02-10

Publications (1)

Publication Number Publication Date
ATE482946T1 true ATE482946T1 (de) 2010-10-15

Family

ID=8241873

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05004285T ATE482946T1 (de) 1999-02-10 2000-02-08 Chinazolinderivate als angiogenesehemmer und zwischenprodukte dafür
AT00902730T ATE298237T1 (de) 1999-02-10 2000-02-08 Chinazolinderivate als angiogenesehemmer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00902730T ATE298237T1 (de) 1999-02-10 2000-02-08 Chinazolinderivate als angiogenesehemmer

Country Status (32)

Country Link
US (3) US7074800B1 (de)
EP (3) EP2050744A1 (de)
JP (3) JP3893026B2 (de)
KR (2) KR100838617B1 (de)
CN (2) CN1167422C (de)
AT (2) ATE482946T1 (de)
AU (1) AU763618B2 (de)
BR (2) BRPI0008128B8 (de)
CA (2) CA2674803C (de)
CY (1) CY1110979T1 (de)
CZ (3) CZ306810B6 (de)
DE (2) DE60020941T2 (de)
DK (2) DK1553097T3 (de)
EE (3) EE05708B1 (de)
ES (2) ES2351699T3 (de)
HK (1) HK1041212B (de)
HU (2) HU228964B1 (de)
ID (1) ID30552A (de)
IL (4) IL144745A0 (de)
IS (2) IS2512B (de)
MX (1) MXPA01008182A (de)
NO (3) NO321604B1 (de)
NZ (2) NZ530832A (de)
PL (2) PL205557B1 (de)
PT (2) PT1154774E (de)
RU (1) RU2262935C2 (de)
SI (2) SI1553097T1 (de)
SK (3) SK288138B6 (de)
TR (2) TR200500745T2 (de)
UA (1) UA73932C2 (de)
WO (1) WO2000047212A1 (de)
ZA (1) ZA200106340B (de)

Families Citing this family (363)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1553097T3 (da) * 1999-02-10 2010-12-13 Astrazeneca Ab Quinazolinderivat som angiogeneseinhibitor og mellemprodukter dertil
PL203782B1 (pl) 1999-11-05 2009-11-30 Astrazeneca Ab Pochodne chinazoliny,sposoby ich wytwarzania,ich kompozycje farmaceutyczne oraz ich zastosowania
JP2003525897A (ja) * 2000-03-06 2003-09-02 アストラゼネカ アクチボラグ 治 療
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
AU779695B2 (en) 2000-04-07 2005-02-10 Astrazeneca Ab Quinazoline compounds
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
AU2001278609B2 (en) * 2000-08-21 2005-04-14 Astrazeneca Ab Quinazoline derivatives
AU2001292138A1 (en) 2000-10-13 2002-04-22 Astrazeneca Ab Quinazoline derivatives with anti-tumour activity
WO2002030926A1 (en) 2000-10-13 2002-04-18 Astrazeneca Ab Quinazoline derivatives
ATE419239T1 (de) 2000-10-20 2009-01-15 Eisai R&D Man Co Ltd Verfahren zur herstellung von 4-phenoxy chinolin derivaten
DE60144284D1 (de) 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
ATE430742T1 (de) 2000-12-21 2009-05-15 Smithkline Beecham Corp Pyrimidinamine als angiogenesemodulatoren
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
PE20020958A1 (es) * 2001-03-23 2002-11-14 Bayer Corp Inhibidores de la rho-quinasa
TWI261055B (en) * 2001-03-23 2006-09-01 Bayer Corp Rho-Kinase Inhibitors
EP1381599B1 (de) * 2001-04-19 2008-09-24 Astrazeneca AB Chinazolin derivate
EP1408980A4 (de) 2001-06-21 2004-10-20 Ariad Pharma Inc Neue chinazoline und ihre verwendungszwecke
ATE341545T1 (de) * 2001-07-16 2006-10-15 Astrazeneca Ab Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase
GB0128109D0 (en) 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
DK1474420T3 (da) 2002-02-01 2012-05-21 Astrazeneca Ab Quinazolinforbindelser
JP4389205B2 (ja) 2002-02-06 2009-12-24 宇部興産株式会社 ４−アミノキナゾリン化合物の製法
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US7504408B2 (en) * 2002-07-09 2009-03-17 Astrazeneca Ab Quinzoline derivatives for use in the treatment of cancer
EP2280003B1 (de) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Verfahren zur Herstellung von Rezeptorkinase-Modulatoren
AU2003257666A1 (en) 2002-08-23 2004-03-11 Kirin Beer Kabushiki Kaisha COMPOUND HAVING TGFss INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME
NZ539408A (en) * 2002-11-04 2007-09-28 Astrazeneca Ab Quinazoline derivatives as SRC tyrosine kinase inhibitors for treating solid tumours
JPWO2004080462A1 (ja) 2003-03-10 2006-06-08 エーザイ株式会社 ｃ−Ｋｉｔキナーゼ阻害剤
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0316127D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0316123D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0318422D0 (en) * 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
GB0318423D0 (en) * 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
KR101028952B1 (ko) * 2003-08-14 2011-04-12 어레이 바이오파마 인크. 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체
MXPA06002964A (es) 2003-09-16 2006-06-14 Astrazeneca Ab Derivados de quinazolina como inhibidores de cinasa de tirosina.
EP2392565B1 (de) 2003-09-26 2014-03-19 Exelixis, Inc. c-Met-Modulatoren und Anwendungsverfahren
CN101337930B (zh) 2003-11-11 2010-09-08 卫材R&D管理有限公司 脲衍生物的制备方法
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
GB0328040D0 (en) * 2003-12-03 2004-01-07 Coleman Robert E Pharmaceutical uses of bisphosphonates
KR100807920B1 (ko) 2003-12-23 2008-02-27 화이자 인코포레이티드 신규한 퀴놀린 유도체
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
WO2005073224A2 (en) * 2004-01-23 2005-08-11 Amgen Inc Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
WO2005070891A2 (en) * 2004-01-23 2005-08-04 Amgen Inc Compounds and methods of use
KR100816960B1 (ko) * 2004-03-17 2008-03-25 화이자 인코포레이티드 2,5-디메틸-2ｈ-피라졸-3-카르복실산｛2-플루오로-5-[3-((ｅ)-2-피리딘-2-일-비닐)-1ｈ-인다졸-6-일아미노]-페닐｝-아미드의 다형성 및 무정질 형태
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
CA2558346A1 (en) * 2004-03-23 2005-10-06 Astrazeneca Ab Combination therapy
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
MXPA06012613A (es) 2004-05-07 2007-01-31 Amgen Inc Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer.
WO2006030947A1 (ja) 2004-09-13 2006-03-23 Eisai R & D Management Co., Ltd. スルホンアミド含有化合物の血管新生阻害物質との併用
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
JP4834553B2 (ja) 2004-09-17 2011-12-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
TW200624431A (en) 2004-09-24 2006-07-16 Hoffmann La Roche Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
MX2007003506A (es) * 2004-09-27 2007-05-10 Aztrazeneca Ab Terapia de combinacion de cancer que comprende azd2171 e imatinib.
AU2005293336B2 (en) 2004-10-12 2009-05-28 Astrazeneca Ab Quinazoline derivatives
JP2008521900A (ja) 2004-11-30 2008-06-26 アムジエン・インコーポレーテツド キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用
WO2006068953A2 (en) 2004-12-21 2006-06-29 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
EP1674467A1 (de) * 2004-12-22 2006-06-28 4Sc Ag 2,5- und 2,6-disubstituierte Benzazol-Derivate zur Verwendung als Protein Kinase Inhibitoren
AU2006233537A1 (en) 2005-04-14 2006-10-19 F. Hoffmann-La Roche Ag Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US8299076B2 (en) 2005-05-18 2012-10-30 Array Biopharma Inc. Crystalline forms of 2-(2-flouro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide
AU2006265835B2 (en) 2005-06-30 2012-05-03 Amgen Inc. Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
WO2007015569A1 (ja) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
EP1925676A4 (de) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd Testverfahren für die wirkung eines vaskularisierungsinhibitors
EP1938842A4 (de) * 2005-09-01 2013-01-09 Eisai R&D Man Co Ltd Verfahren zur herstellung einer pharmazeutischen zusammensetzung mit verbesserten zerfallseigenschaften
US8247556B2 (en) 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
JPWO2007052849A1 (ja) * 2005-11-07 2009-04-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質とｃ−ｋｉｔキナーゼ阻害物質との併用
WO2007061127A1 (ja) * 2005-11-22 2007-05-31 Eisai R & D Management Co., Ltd. 多発性骨髄腫に対する抗腫瘍剤
GB0523810D0 (en) 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions
BRPI0620118A2 (pt) * 2005-12-22 2011-11-01 Astrazeneca Ab uso de azd2171 ou de um sal farmaceuticamente aceitável do mesmo e de permetrexed, composição farmacêutica, kit, e, método para a produção de um efeito de redução da permeabilidade antiangiogênica, e/ou vascular em um animal de sangue quente
US7868177B2 (en) 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
US20070287707A1 (en) * 2006-02-28 2007-12-13 Arrington Mark P Phosphodiesterase 10 inhibitors
EP1994024A2 (de) * 2006-03-02 2008-11-26 AstraZeneca AB Chinolinderivate
UY30183A1 (es) * 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
RU2448708C3 (ru) * 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство против рака щитовидной железы
EP2044939A1 (de) * 2006-06-29 2009-04-08 Eisai R&D Management Co., Ltd. Therapeutisches mittel gegen leberfibrose
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
AU2007287430B2 (en) 2006-08-23 2011-07-21 Kudos Pharmaceuticals Limited 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
EP2061469B8 (de) 2006-09-11 2014-02-26 Curis, Inc. Chinazolin-basierte egfr-hemmer
AU2012204077B2 (en) * 2006-11-02 2012-11-29 Astrazeneca Ab Process for preparing indol-5-oxy-quinazoline derivatives and intermediates
CL2007003158A1 (es) * 2006-11-02 2008-05-16 Astrazeneca Ab Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion.
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
US8338455B2 (en) 2006-12-20 2012-12-25 Amgen Inc. Compounds and methods of use
WO2008093855A1 (ja) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. 未分化型胃癌治療用組成物
EA200901041A1 (ru) 2007-02-06 2010-02-26 Бёрингер Ингельхайм Интернациональ Гмбх Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
US8148532B2 (en) 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
US8044056B2 (en) 2007-03-20 2011-10-25 Dainippon Sumitomo Pharma Co., Ltd. Adenine compound
AR065784A1 (es) 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
US20100130519A1 (en) * 2007-04-13 2010-05-27 Stephen Robert Wedge Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii
NZ580671A (en) 2007-04-16 2012-03-30 Hutchison Medipharma Entpr Ltd Pyrimidine derivatives
WO2009030224A2 (de) * 2007-09-07 2009-03-12 Schebo Biotech Ag Neue chinazolin- verbindungen und ihre verwendung zur therapie von krebserkrankungen
TW200922590A (en) * 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
ES2526718T3 (es) 2007-09-10 2015-01-14 Curis, Inc. Inhibidores de EGFR basados en sales de tartrato o complejos de quinazolina que contienen un resto que se une al cinc
US8119616B2 (en) 2007-09-10 2012-02-21 Curis, Inc. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
AU2008309383B2 (en) 2007-10-11 2012-04-19 Astrazeneca Ab Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors
MX2010004620A (es) * 2007-10-29 2010-07-28 Amgen Inc Derivados de benzomorfolina y metodos de uso.
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
EP2690101B1 (de) 2007-12-19 2015-06-24 Genentech, Inc. 5-Anilin-Imidazopyridine und Verfahren zu ihrer Verwendung
NZ586575A (en) 2007-12-21 2012-03-30 Genentech Inc Azaindolizines and methods of use
CN101215274B (zh) * 2007-12-27 2011-05-04 上海北卡医药技术有限公司 N取代吗啉类有机化合物的制备工艺
EP2247579B1 (de) * 2008-01-17 2012-04-18 Bayer Pharma Aktiengesellschaft Sulfoximinsubstituierte chinazolinderivate als immunmodulatoren, ihre herstellung und ihre verwendung als medikamente
WO2009094211A1 (en) * 2008-01-22 2009-07-30 Concert Pharmaceuticals Inc. Quinazoline compounds and methods of treating cancer
MX2010008187A (es) * 2008-01-29 2010-08-10 Eisai R&D Man Co Ltd Uso combinado de inhibidor de angiogenesis y taxano.
JP5336516B2 (ja) 2008-02-07 2013-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング スピロ環式複素環化合物、該化合物を含む医薬品、その使用及びその製造方法
JP2011512395A (ja) * 2008-02-21 2011-04-21 アストラゼネカ アクチボラグ 組合せ療法２３８
JP5519627B2 (ja) * 2008-03-26 2014-06-11 ノバルティス アーゲー Ｖｅｇｆ促進性血管新生過程の強力なモジュレーターとしての５イミダゾキノリン誘導体およびピリミジン誘導体
US7829574B2 (en) * 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
BRPI0912170A2 (pt) 2008-05-13 2015-10-13 Astrazeneca Ab composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
US8426430B2 (en) 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
EP2149565A1 (de) * 2008-07-24 2010-02-03 Bayer Schering Pharma AG Sulfonsubstituierte Chinazolinderivate als Immunmodulatoren zur Behandlung von enzündlichen und allergischen Erkrankungen
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
US8211911B2 (en) * 2008-08-19 2012-07-03 Guoqing Paul Chen Compounds as kinase inhibitors
US7737157B2 (en) 2008-08-29 2010-06-15 Hutchison Medipharma Enterprises Limited Pyrimidine compounds
EP2344536A1 (de) 2008-09-19 2011-07-20 MedImmune, LLC Gegen dll4 gerichtete antikörper und anwendungen davon
AU2009303602B2 (en) 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
TW201028410A (en) 2008-12-22 2010-08-01 Astrazeneca Ab Chemical compounds 610
JP2012513194A (ja) 2008-12-23 2012-06-14 アストラゼネカ アクチボラグ α５β１に向けられた標的結合剤およびその使用
RS52754B2 (sr) 2009-01-16 2022-08-31 Exelixis Inc Malat so n-(4- {[6,7-bis(metiloksi)hinolin-4-il]oksi}fenil-n'- (4-fluorofenil) ciklopropan-1,1-dikarboksamid-a, i njeni kristalni oblici za lečenje karcinoma
SG173152A1 (en) 2009-02-05 2011-08-29 Immunogen Inc Novel benzodiazepine derivatives
WO2010089580A1 (en) 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
EP2396333B1 (en) 2009-02-10 2013-07-03 AstraZeneca AB Triazolo[4,3-b]pyridazine derivatives and their uses for prostate cancer
EP2406258B1 (de) 2009-03-13 2014-12-03 Cellzome Limited Pyrimidin-derivate als mtor-hemmer
IT1393351B1 (it) * 2009-03-16 2012-04-20 Eos Ethical Oncology Science Spa In Forma Abbreviata Eos Spa Procedimento per la preparazione della 6-(7-((1-amminociclopropil)metossi)-6-metossichinolin-4-ilossi)-n-metil-1-naftammide e suoi intermedi di sintesi
KR20110133048A (ko) * 2009-03-21 2011-12-09 닝 시 아미노 에스테르 유도체, 그의 염 및 이용 방법
GB0905127D0 (en) 2009-03-25 2009-05-06 Pharminox Ltd Novel prodrugs
EP2419423A1 (de) 2009-04-14 2012-02-22 Cellzome Limited Fluorsubstituierte pyridinverbindungen als jak3-inhibitoren
US8389580B2 (en) 2009-06-02 2013-03-05 Duke University Arylcyclopropylamines and methods of use
US20100317593A1 (en) 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
TH121482A (th) 2009-08-19 2013-02-28 นางสาวปัณณพัฒน์ เหลืองธาตุทอง องค์ประกอบทางเภสัชกรรมที่ประกอบด้วยอนุพันธ์ของควิโนลีน
CA2771675A1 (en) 2009-09-11 2011-03-17 Cellzome Limited Ortho substituted pyrimidine compounds as jak inhibitors
AU2010309882B2 (en) 2009-10-20 2016-01-28 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors
US8399460B2 (en) 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
KR20120113709A (ko) 2009-11-18 2012-10-15 아스트라제네카 아베 벤조이미다졸 화합물 및 그의 용도
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
EP2507237A1 (de) 2009-12-03 2012-10-10 Dainippon Sumitomo Pharma Co., Ltd. Über toll-like-rezeptoren (tlr) agierende imidazochinoline
US9180127B2 (en) * 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
CN103980338B (zh) 2010-01-15 2017-04-26 苏州润新生物科技有限公司 蟾蜍灵衍生物、其药物组合物及用途
US8198285B2 (en) 2010-01-19 2012-06-12 Astrazeneca Ab Pyrazine derivatives
WO2011095807A1 (en) 2010-02-07 2011-08-11 Astrazeneca Ab Combinations of mek and hh inhibitors
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
EP2542536B1 (de) 2010-03-04 2015-01-21 Cellzome Limited Morpholinsubstituierte Harnstoff-Derivate als mTOR-Hemmer
EP2566867A1 (de) 2010-04-30 2013-03-13 Cellzome Limited Pyrazolverbindungen als jak-hemmer
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
AU2011270165B2 (en) 2010-06-25 2015-12-24 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
US20130143915A1 (en) 2010-07-01 2013-06-06 Cellzome Limited Triazolopyridines as tyk2 inhibitors
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
JP2013534233A (ja) 2010-08-20 2013-09-02 セルゾーム リミティッド 選択的ｊａｋ阻害剤としてのヘテロシクリルピラゾロピリミジン類似体
CN102656179B (zh) 2010-08-28 2015-07-29 苏州润新生物科技有限公司 蟾蜍灵衍生物、其药物组合物及用途
GB201016442D0 (en) 2010-09-30 2010-11-17 Pharminox Ltd Novel acridine derivatives
CN103298794A (zh) 2010-11-09 2013-09-11 塞尔卓姆有限公司 作为tyk2抑制剂的吡啶化合物及其氮杂类似物
WO2012067269A1 (en) 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Aminoalkoxyphenyl compounds and their use in the treatment of disease
WO2012066335A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Phenol compounds als toll -like receptor 7 agonists
EP2640716A1 (de) 2010-11-19 2013-09-25 Dainippon Sumitomo Pharma Co., Ltd. Cyclische amidverbindungen und ihre verwendung bei der behandlung von erkrankungen
WO2012066336A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Benzylamine compounds as toll -like receptor 7 agonists
EP3453714B1 (de) 2011-02-02 2020-11-04 Suzhou Neupharma Co., Ltd Cardenolid- und bufadienolid- 3-carbonate and 3-carbamate derivative zur behandlung von krebs sowie zusammensetzungen davon
KR20190089048A (ko) 2011-02-15 2019-07-29 이뮤노젠 아이엔씨 컨쥬게이트의 제조방법
DK2675793T3 (en) 2011-02-17 2018-11-12 Cancer Therapeutics Crc Pty Ltd FAK INHIBITORS
EP2675794B1 (de) 2011-02-17 2019-02-13 Cancer Therapeutics Crc Pty Limited Selektive fak-inhibitoren
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
US20140163023A1 (en) 2011-04-04 2014-06-12 Cellzome Limited Dihydropyrrolo pyrimidine derivatives as mtor inhibitors
US8530470B2 (en) 2011-04-13 2013-09-10 Astrazeneca Ab Chromenone derivatives
WO2012144463A1 (ja) 2011-04-18 2012-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
WO2012143320A1 (en) 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
EP3444363B1 (de) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarker zur vorhersage und beurteilung des ansprechens von schilddrüsen- und nierenkrebspatienten auf lenvatinibverbindungen
WO2012175991A1 (en) 2011-06-24 2012-12-27 Pharminox Limited Fused pentacyclic anti - proliferative compounds
EP2736895B1 (de) 2011-07-27 2016-01-06 Astrazeneca AB 2-(2,4,5-substituted-anilino) pyrimidine derivate als egfr modulatoren zur behandlung von krebs
CN103781780B (zh) 2011-07-28 2015-11-25 赛尔佐姆有限公司 作为jak抑制剂的杂环基嘧啶类似物
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013017479A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013032951A1 (en) 2011-08-26 2013-03-07 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2013033250A1 (en) 2011-09-01 2013-03-07 Xiangping Qian Certain chemical entities, compositions, and methods
EP3332785B1 (de) 2011-09-14 2020-05-06 Neupharma, Inc. Bestimmte chemische stoffe, zusammensetzungen und verfahren
EP2760863A1 (de) 2011-09-20 2014-08-06 Cellzome Limited Pyrazol[4,3-c]pyridin-derivate als kinaseinhibitoren
EP2758379B1 (de) 2011-09-21 2016-10-19 Cellzome Limited Harnstoff- und Carbamatderivate des 2-Morpholino-1,3,5-Triazins als mTOR Inhibitoren zur Behandlung von immunologischen oder proliferative Erkrankungen
EP2757885B1 (de) 2011-09-21 2017-03-15 Neupharma, Inc. Bestimmte chemische stoffe, zusammensetzungen und verfahren
US20140235573A1 (en) 2011-09-29 2014-08-21 The University Of Liverpool Prevention and/or treatment of cancer and/or cancer metastasis
US9249111B2 (en) 2011-09-30 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-RAF kinase inhibitors
AU2012320465B2 (en) 2011-10-07 2016-03-03 Cellzome Limited Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
US20150005281A1 (en) 2011-12-23 2015-01-01 Cellzome Limited Pyrimidine-2,4-diamine derivatives as kinase inhibitors
EP2806874B1 (de) 2012-01-25 2017-11-15 Neupharma, Inc. Quinoxalin-oxy-phenyl derivate als Kinase-Inhibitoren
EP2626066A1 (de) 2012-02-10 2013-08-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Kombinationstherapie mit selektiven VEGFR-2-Inhibitoren und MEK-Inhibitoren
EP2852285B1 (de) 2012-04-29 2018-08-08 Neupharma, Inc. Bufadienolidverbindungen mit einer 3-heterozyklischen amingruppe zur behandlung von krebs
ES2718478T3 (es) 2012-06-08 2019-07-02 Sutro Biopharma Inc Anticuerpos que comprenden restos de aminoácidos no naturales de localización específica, métodos para su preparación y métodos para su uso
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
US9238644B2 (en) 2012-08-17 2016-01-19 Cancer Therapeutics Crc Pty Limited VEGFR3 inhibitors
EP2887965A1 (de) 2012-08-22 2015-07-01 ImmunoGen, Inc. Zytotoxische benzodiazepin-derivate
SG11201501464TA (en) 2012-08-31 2015-03-30 Sutro Biopharma Inc Modified amino acids comprising an azido group
WO2014041349A1 (en) 2012-09-12 2014-03-20 Cancer Therapeutics Crc Pty Ltd Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
WO2014045101A1 (en) 2012-09-21 2014-03-27 Cellzome Gmbh Tetrazolo quinoxaline derivatives as tankyrase inhibitors
CN104812389B (zh) 2012-09-24 2020-07-17 润新生物公司 某些化学实体、组合物及方法
AU2013337297A1 (en) 2012-11-05 2015-05-21 Nantbio, Inc. Substituted indol-5-ol derivatives and their therapeutical applications
WO2014075077A1 (en) 2012-11-12 2014-05-15 Neupharma, Inc. Certain chemical entities, compositions, and methods
RU2015115397A (ru) 2012-12-21 2017-01-25 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Аморфная форма производного хинолина и способ его получения
US9598409B2 (en) 2013-01-31 2017-03-21 Neomed Institute Imidazopyridine compounds and uses thereof
HK1217092A1 (zh) 2013-02-15 2016-12-23 Kala Pharmaceuticals, Inc. 治疗性化合物及其用途
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
BR112015020139A2 (pt) * 2013-02-20 2017-07-18 Kala Pharmaceuticals Inc compostos terapêuticos e usos dos mesmos
WO2014134483A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
US9901647B2 (en) 2013-02-28 2018-02-27 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
EP3293185A1 (de) 2013-03-13 2018-03-14 AbbVie Inc. Verfahren zur herstellung eines apoptoseauslösers
AR095443A1 (es) 2013-03-15 2015-10-14 Fundación Centro Nac De Investig Oncológicas Carlos Iii Heterociclos condensados con acción sobre atr
US9937137B2 (en) 2013-03-15 2018-04-10 Neurocentria, Inc. Magnesium compositions and uses thereof for cancers
WO2014145403A1 (en) 2013-03-15 2014-09-18 Nantbio, Inc. Substituted indol-5-ol derivatives and their therapeutic applications
ES2899726T3 (es) 2013-04-09 2022-03-14 Guangzhou Kangrui Biological Pharmaceutical Tech Co Ltd Compuesto antiangiogénesis, intermediario y uso del mismo
ES2687968T3 (es) 2013-05-14 2018-10-30 Eisai R&D Management Co., Ltd. Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib
EP2806480B1 (de) * 2013-05-20 2017-08-09 Nintendo Co., Ltd. Batterieaufnahmestruktur und Batterieaufnahmeverfahren
CN103275069B (zh) * 2013-05-22 2015-03-11 苏州明锐医药科技有限公司 西地尼布的制备方法
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2014195507A1 (en) 2013-06-07 2014-12-11 Universite Catholique De Louvain 3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases
US9764039B2 (en) 2013-07-10 2017-09-19 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
NZ718190A (en) 2013-08-23 2017-10-27 Neupharma Inc Substituted quinazolines for inhibiting kinase activity
CN103509005B (zh) * 2013-09-26 2015-04-08 苏州海特比奥生物技术有限公司 喹唑啉类化合物及其制备方法与应用
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
EP2868702A1 (de) 2013-10-29 2015-05-06 DyStar Colours Distribution GmbH Dispersfarbstoffe, Herstellung und Verwendung
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
CA3109285A1 (en) * 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
KR20230043234A (ko) 2014-08-28 2023-03-30 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
CN105461698A (zh) * 2014-09-12 2016-04-06 杭州普晒医药科技有限公司 西地尼布盐及其晶型、以及其制备方法和药物组合物
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
GB201501870D0 (en) 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
EP3270694A4 (de) 2015-02-17 2018-09-05 Neupharma, Inc. Bestimmte chemische einheiten, zusammensetzungen und verfahren
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
MX373231B (es) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
EP3957637B1 (de) 2015-08-04 2023-06-28 Aucentra Therapeutics Pty Ltd N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amin-derivate als therapeutische verbindungen
CA2994925C (en) 2015-08-20 2023-08-29 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
WO2017062500A2 (en) 2015-10-05 2017-04-13 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
SG11201806419RA (en) 2016-01-27 2018-08-30 Sutro Biopharma Inc Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
EP4071174A1 (de) 2016-02-15 2022-10-12 AstraZeneca AB Verfahren mit fixer intermittierender dosierung von cediranib
SMT202200348T1 (it) 2016-04-15 2022-11-18 Cancer Research Tech Ltd Composti eterociclici come inibitori della chinasi ret
GB2554333A (en) 2016-04-26 2018-04-04 Big Dna Ltd Combination therapy
AU2017312561B2 (en) 2016-08-15 2022-06-30 Neupharma, Inc. Certain chemical entities, compositions, and methods
US10870694B2 (en) 2016-09-02 2020-12-22 Dana Farber Cancer Institute, Inc. Composition and methods of treating B cell disorders
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036336A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (de) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. Kristalline formen von therapeutischen verbindungen und verwendungen davon
JP7118974B2 (ja) 2016-09-22 2022-08-16 キャンサー・リサーチ・テクノロジー・リミテッド ピリミジノン誘導体の調製および使用
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
JP6755775B2 (ja) * 2016-11-04 2020-09-16 富士アミドケミカル株式会社 ４−フルオロイソキノリンの製法
CA3041563C (en) 2016-11-22 2023-10-31 Dana-Farber Cancer Institute, Inc. Pyrimidin-2-amine derivatives and pharmaceutical compositions thereof useful as inhibitors of cyclin-dependent kinase 12 (cdk12)
JP7071392B2 (ja) 2016-12-05 2022-05-18 アプロス セラピューティクス， インコーポレイテッド 酸性基を含有するピリミジン化合物
US10786502B2 (en) 2016-12-05 2020-09-29 Apros Therapeutics, Inc. Substituted pyrimidines containing acidic groups as TLR7 modulators
CN106831729A (zh) * 2016-12-19 2017-06-13 浙江工业大学 一种西地尼布的纯化方法
EP3577116B1 (de) 2017-02-01 2025-04-23 Changzhou Qianhong Bio-Pharma Co., Ltd Derivate von n-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridin)pyrimidin-2-amin als therapeutika
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
GB201704325D0 (en) 2017-03-17 2017-05-03 Argonaut Therapeutics Ltd Compounds
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
CN108864079B (zh) 2017-05-15 2021-04-09 深圳福沃药业有限公司 一种三嗪化合物及其药学上可接受的盐
BR112019023064A2 (pt) 2017-05-16 2020-06-09 Eisai R&D Man Co Ltd tratamento de carcinoma hepatocelular
EP4371562A3 (de) 2017-05-26 2024-08-14 Cancer Research Technology Limited Vom 2-chinolon abgeleitete hemmer von bcl6
WO2018215801A1 (en) 2017-05-26 2018-11-29 Cancer Research Technology Limited Benzimidazolone derived inhibitors of bcl6
EP3658588A1 (de) 2017-07-26 2020-06-03 Sutro Biopharma, Inc. Verfahren zur verwendung von anti-cd74-antikörpern und antikörperkonjugaten bei der behandlung von t-zell-lymphomen
EP3668882A1 (de) 2017-08-18 2020-06-24 Cancer Research Technology Limited Pyrrolo-[2,3-b]pyridinverbindungen und ihre verwendung zur behandlung von krebs
KR20200051802A (ko) 2017-09-18 2020-05-13 서트로 바이오파마, 인크. 항-엽산 수용체 알파 항체 접합체 및 이의 용도
AU2018351520A1 (en) * 2017-10-20 2020-05-07 Kala Pharmaceuticals, Inc. RET9 and VEGFR2 inhibitors
NL2019801B1 (en) 2017-10-25 2019-05-02 Univ Leiden Delivery vectors
AU2019207517A1 (en) 2018-01-15 2020-08-27 Aucentra Therapeutics Pty Ltd 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents
GB201801128D0 (en) 2018-01-24 2018-03-07 Univ Oxford Innovation Ltd Compounds
KR20200143361A (ko) 2018-02-08 2020-12-23 뉴파마, 인크. 특정 화학 물질, 조성물, 및 방법
WO2019175093A1 (en) 2018-03-12 2019-09-19 Astrazeneca Ab Method for treating lung cancer
SG11202009735QA (en) 2018-04-13 2020-10-29 Cancer Research Tech Ltd Bcl6 inhibitors
FR3080620B1 (fr) 2018-04-27 2021-11-12 Univ Paris Sud Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
EP3802519A1 (de) 2018-06-04 2021-04-14 Apros Therapeutics, Inc. Pyrimidinverbindungen mit sauren gruppen zur behandlung von krankheiten im zusammenhang mit der modulation von tlr7
GB201809102D0 (en) 2018-06-04 2018-07-18 Univ Oxford Innovation Ltd Compounds
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
US20220047716A1 (en) 2018-09-17 2022-02-17 Sutro Biopharma, Inc. Combination therapies with anti-folate receptor antibody conjugates
CN112996784B (zh) * 2018-09-18 2023-05-30 北京越之康泰生物医药科技有限公司 吲哚衍生物及其在医药上的应用
WO2020068867A1 (en) 2018-09-25 2020-04-02 Black Diamond Therapeutics, Inc. Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
GB201819126D0 (en) 2018-11-23 2019-01-09 Cancer Research Tech Ltd Inhibitor compounds
WO2020174283A1 (en) 2019-02-25 2020-09-03 Bellus Health Cough Inc. Treatment with p2x3 modulators
KR102861189B1 (ko) 2019-03-28 2025-09-16 앰플리아 테라퓨틱스 리미티드 Fak 억제제의 염 및 결정 형태
CN113645976A (zh) 2019-03-29 2021-11-12 阿斯利康(瑞典)有限公司 用于治疗非小细胞肺癌的奧希替尼
CN111747950B (zh) 2019-03-29 2024-01-23 深圳福沃药业有限公司 用于治疗癌症的嘧啶衍生物
EP3946618A1 (de) 2019-04-05 2022-02-09 Storm Therapeutics Ltd Mettl3-hemmende verbindungen
GB201905328D0 (en) 2019-04-15 2019-05-29 Azeria Therapeutics Ltd Inhibitor compounds
WO2020227105A1 (en) 2019-05-03 2020-11-12 Sutro Biopharma, Inc. Anti-bcma antibody conjugates
GB201908885D0 (en) 2019-06-20 2019-08-07 Storm Therapeutics Ltd Therapeutic compounds
WO2021030711A1 (en) 2019-08-15 2021-02-18 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
JP2022545930A (ja) 2019-08-31 2022-11-01 上海奕拓醫藥科技有限責任公司 Ｆｇｆｒ阻害剤とするピラゾール類誘導体及びその調製方法
US20220389003A1 (en) 2019-09-20 2022-12-08 Ideaya Biosciences, Inc. 4-substituted indole and indazole sulfonamido derivatives as parg inhibitors
GB201913988D0 (en) 2019-09-27 2019-11-13 Celleron Therapeutics Ltd Novel treatment
GB201914860D0 (en) 2019-10-14 2019-11-27 Cancer Research Tech Ltd Inhibitor compounds
GB201915831D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915828D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915829D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
MX2022006700A (es) 2019-12-02 2022-09-02 Storm Therapeutics Ltd Compuestos poliheterociclicos como inhibidores de mettl3.
US20230095053A1 (en) 2020-03-03 2023-03-30 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
GB202004960D0 (en) 2020-04-03 2020-05-20 Kinsenus Ltd Inhibitor compounds
GB202012969D0 (en) 2020-08-19 2020-09-30 Univ Of Oxford Inhibitor compounds
WO2022074379A1 (en) 2020-10-06 2022-04-14 Storm Therapeutics Limited Mettl3 inhibitory compounds
US20240101589A1 (en) 2020-10-08 2024-03-28 Strom Therapeutics Limited Inhibitors of mettl3
GB202102895D0 (en) 2021-03-01 2021-04-14 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
KR102733257B1 (ko) 2021-05-17 2024-11-26 에이치케이이노엔 주식회사 벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
GB202107907D0 (en) 2021-06-02 2021-07-14 Storm Therapeutics Ltd Combination therapies
GB202108383D0 (en) 2021-06-11 2021-07-28 Argonaut Therapeutics Ltd Compounds useful in the treatment or prevention of a prmt5-mediated disorder
EP4384223B1 (de) 2021-08-13 2025-10-01 GlaxoSmithKline Intellectual Property Development Limited Auf zytotoxizität abzielende chimäre für ccr2-exprimierende zellen
US20250002491A1 (en) 2021-10-04 2025-01-02 Forx Therapeutics Ag N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
WO2024074497A1 (en) 2022-10-03 2024-04-11 Forx Therapeutics Ag Parg inhibitory compound
AU2022359801A1 (en) 2021-10-04 2024-02-01 Forx Therapeutics Ag Parg inhibitory compounds
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
GB202202199D0 (en) 2022-02-18 2022-04-06 Cancer Research Tech Ltd Compounds
WO2023161881A1 (en) * 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for ccr2-expressing cells
WO2023175184A1 (en) 2022-03-17 2023-09-21 Forx Therapeutics Ag 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
WO2023175185A1 (en) 2022-03-17 2023-09-21 Forx Therapeutics Ag 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
GB202204935D0 (en) 2022-04-04 2022-05-18 Cambridge Entpr Ltd Nanoparticles
GB202209404D0 (en) 2022-06-27 2022-08-10 Univ Of Sussex Compounds
WO2024003241A1 (en) 2022-06-30 2024-01-04 Astrazeneca Ab Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4
EP4547284A1 (de) 2022-06-30 2025-05-07 Sutro Biopharma, Inc. Anti-ror1-antikörper und antikörperkonjugate, zusammensetzungen mit anti-ror1-antikörpern oder antikörperkonjugaten sowie verfahren zur herstellung und verwendung von anti-ror1-antikörpern und antikörperkonjugaten
EP4565592A1 (de) 2022-08-01 2025-06-11 Neupharma, Inc. Kristalline salze von (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2-oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a!phenanthren-3-ylpiperazincarboxylat
GB202213166D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213167D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213163D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213164D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2024059169A1 (en) * 2022-09-14 2024-03-21 Blueprint Medicines Corporation Egfr inhibitors
WO2024094963A1 (en) 2022-11-02 2024-05-10 Cancer Research Technology Limited 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one and 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1 h)-one derivatives as egfr inhibitors for the treatment of cancer
EP4612149A1 (de) 2022-11-02 2025-09-10 Cancer Research Technology Limited Pyrido[2,3-d pyrimidin-2-aminderivate als egfr-hemmer zur behandlung von krebs
GB202218672D0 (en) 2022-12-12 2023-01-25 Storm Therapeutics Ltd Inhibitory compounds
WO2024173524A1 (en) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted benzimidazole compounds
WO2024173453A1 (en) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted imidazopyridine compounds
WO2024173530A1 (en) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted pyrazolo/imidazo pyridine compounds
WO2024173514A1 (en) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Amide and ester-substituted imidazopyridine compounds
JP2026509311A (ja) 2023-03-10 2026-03-17 ブレークポイント・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｄｎａポリメラーゼシータの阻害剤
EP4688159A1 (de) 2023-04-05 2026-02-11 FoRx Therapeutics AG Parg-hemmende verbindungen
GB2631509A (en) 2023-07-04 2025-01-08 Univ Liverpool Compositions
GB2631507A (en) 2023-07-04 2025-01-08 Univ Liverpool Compositions
WO2025046148A1 (en) 2023-09-01 2025-03-06 Forx Therapeutics Ag Novel parg inhibitors
WO2025056923A1 (en) 2023-09-15 2025-03-20 Cambridge Enterprise Limited Combination therapy
WO2025073792A1 (en) 2023-10-02 2025-04-10 Forx Therapeutics Ag Wrn inhibitory compounds
WO2025073870A1 (en) 2023-10-03 2025-04-10 Forx Therapeutics Ag Parg inhibitory compound
GB202315149D0 (en) 2023-10-03 2023-11-15 Celleron Therapeutics Ltd Combination therapy
US12540197B2 (en) 2023-10-13 2026-02-03 Sutro Biopharma, Inc. Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
GB202316595D0 (en) 2023-10-30 2023-12-13 Storm Therapeutics Ltd Inhibitory compounds
GB202316683D0 (en) 2023-10-31 2023-12-13 Storm Therapeutics Ltd Inhibitory compounds
WO2025093755A1 (en) 2023-11-01 2025-05-08 Forx Therapeutics Ag Novel parc inhibitors
GB202317368D0 (en) 2023-11-13 2023-12-27 Breakpoint Therapeutics Gmbh Novel compounds, compositions and therapeutic uses thereof
WO2025104443A1 (en) 2023-11-14 2025-05-22 Storm Therapeutics Ltd Inhibitory compounds
WO2025114480A1 (en) 2023-11-28 2025-06-05 Forx Therapeutics Ag Wrn inhibitory compounds
WO2025136811A1 (en) 2023-12-18 2025-06-26 Ideaya Biosciences, Inc. Chemical compounds and uses thereof
GB202319863D0 (en) 2023-12-21 2024-02-07 Breakpoint Therapeutics Gmbh Movel compounds, compositions and therapeutics uses thereof
WO2025133396A1 (en) 2023-12-22 2025-06-26 Forx Therapeutics Ag Novel bicyclo heteroaryl parg inhibitors
WO2025133395A1 (en) 2023-12-22 2025-06-26 Forx Therapeutics Ag Bicyclic (hetero)arylene wrn inhibitory compounds
WO2025191176A1 (en) 2024-03-14 2025-09-18 Forx Therapeutics Ag Wrn inhibitory compounds
NL2037411B1 (en) 2024-04-08 2025-10-31 Univ Leiden Protac compounds
WO2025250825A1 (en) 2024-05-30 2025-12-04 Sutro Biopharma, Inc. Anti-trop2 antibodies, compositions comprising anti-trop2 antibodies and methods of making and using anti-trop2 antibodies
GB202407738D0 (en) 2024-05-31 2024-07-17 Storm Therapeutics Ltd Inhibitory compounds
WO2025262192A1 (en) 2024-06-21 2025-12-26 Breakpoint Therapeutics Gmbh Quinazoline derivatives suitable for use as werner syndrome helicase protein inhibitors
WO2026003380A1 (en) 2024-06-28 2026-01-02 Forx Therapeutics Ag Wrn inhibitory compounds
WO2026022150A1 (en) 2024-07-22 2026-01-29 Forx Therapeutics Ag Parg inhibitory compounds
WO2026043823A2 (en) 2024-08-19 2026-02-26 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof
CN119198978B (zh) * 2024-11-29 2025-02-11 天津医科大学总医院空港医院 一种生物样本中血小板生成素受体激动剂的检测方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3557142A (en) * 1968-02-20 1971-01-19 Sterling Drug Inc 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
US4460584A (en) 1981-03-13 1984-07-17 Imperial Chemical Industries Plc Nitrogen heterocycles
IL81307A0 (en) 1986-01-23 1987-08-31 Union Carbide Agricult Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives
US5411963A (en) 1988-01-29 1995-05-02 Dowelanco Quinazoline derivatives
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
GB8819307D0 (en) 1988-08-13 1988-09-14 Pfizer Ltd Antiarrhythmic agents
US6645969B1 (en) 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5714493A (en) 1991-05-10 1998-02-03 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
AU658646B2 (en) 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9205320D0 (en) * 1992-03-11 1992-04-22 Ici Plc Anti-tumour compounds
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
AU686843B2 (en) 1994-02-23 1998-02-12 Pfizer Inc. 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents
AU2096895A (en) 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
US5773449A (en) 1994-10-07 1998-06-30 Zenyaku Kogyo Kabushiki Kaisha Thioquinolone compounds which have useful pharmaceutical activity
DE4436509A1 (de) * 1994-10-13 1996-04-18 Hoechst Schering Agrevo Gmbh Substituierte Spiroalkylamino- und alkoxy-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
GB9505651D0 (en) * 1995-03-21 1995-05-10 Agrevo Uk Ltd AgrEvo UK Limited
US6046206A (en) 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
WO1997017329A1 (en) 1995-11-07 1997-05-15 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE19614718A1 (de) 1996-04-15 1997-10-16 Hoechst Schering Agrevo Gmbh Substituierte Pyridine/Pyrimidine, Verfahren zu ihrer Herstellung, und ihre Verwendung als Schädlingsbekämpfungsmittel
GB9707800D0 (en) * 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
GB9609641D0 (en) * 1996-05-09 1996-07-10 Pfizer Ltd Compounds useful in therapy
GB9613021D0 (en) * 1996-06-21 1996-08-28 Pharmacia Spa Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
JP4386967B2 (ja) 1996-07-13 2009-12-16 グラクソ、グループ、リミテッド プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物
WO1998013350A1 (en) * 1996-09-25 1998-04-02 Zeneca Limited Qinoline derivatives inhibiting the effect of growth factors such as vegf
EP0837063A1 (de) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazolinderivate
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
AU734009B2 (en) 1997-05-30 2001-05-31 Merck & Co., Inc. Novel angiogenesis inhibitors
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ATE368665T1 (de) * 1997-08-22 2007-08-15 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
WO1999028159A1 (de) 1997-11-27 1999-06-10 Continental Teves Ag & Co. Ohg Verfahren und vorrichtung zum versorgen von kraftfahrzeugen mit daten oder zum datenaustausch
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
US6172071B1 (en) 1998-07-30 2001-01-09 Hughes Institute Lipid-lowering quinazoline derivative
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
GB2345486A (en) 1999-01-11 2000-07-12 Glaxo Group Ltd Heteroaromatic protein tyrosine kinase inhibitors
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
DK1553097T3 (da) * 1999-02-10 2010-12-13 Astrazeneca Ab Quinazolinderivat som angiogeneseinhibitor og mellemprodukter dertil
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
DZ3223A1 (fr) 1999-10-19 2001-04-26 Merck & Co Inc Inhibiteurs de tyrosine kinases
WO2002012227A2 (en) 2000-08-09 2002-02-14 Astrazeneca Ab Indole, azaindole and indazole derivatives having vegf inhibiting activity
WO2002012228A1 (en) 2000-08-09 2002-02-14 Astrazeneca Ab Cinnoline compounds
JP2004505964A (ja) 2000-08-09 2004-02-26 アストラゼネカ　アクチボラグ Ｖｅｇｆ阻害活性を有するキノリン誘導体
DK1474420T3 (da) * 2002-02-01 2012-05-21 Astrazeneca Ab Quinazolinforbindelser
GB0318422D0 (en) 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
GB0523810D0 (en) * 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions
CL2007003158A1 (es) 2006-11-02 2008-05-16 Astrazeneca Ab Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion.

Also Published As

Publication number Publication date
EE200100409A (et) 2002-12-16
DE60020941T2 (de) 2006-05-11
IS2512B (is) 2009-05-15
BRPI0017548A2 (pt) 2010-07-27
US20120197027A1 (en) 2012-08-02
CN1167422C (zh) 2004-09-22
HK1041212A1 (en) 2002-07-05
CZ305827B6 (cs) 2016-03-30
IS8708A (is) 2008-01-25
HU230000B1 (en) 2015-04-28
KR20080015482A (ko) 2008-02-19
AU763618B2 (en) 2003-07-31
ATE298237T1 (de) 2005-07-15
ES2242596T3 (es) 2005-11-16
JP2006273860A (ja) 2006-10-12
NO20052773L (no) 2001-10-09
PT1553097E (pt) 2010-12-13
BR0008128B1 (pt) 2014-11-18
EP1553097B1 (de) 2010-09-29
HK1041212B (en) 2005-12-02
HK1076104A1 (zh) 2006-01-06
DK1154774T3 (da) 2005-09-26
JP4651576B2 (ja) 2011-03-16
KR100838617B1 (ko) 2008-06-16
SK11402001A3 (sk) 2002-01-07
IL144745A0 (en) 2002-06-30
MXPA01008182A (es) 2003-08-20
BRPI0008128B8 (pt) 2021-05-25
PL205557B1 (pl) 2010-05-31
AU2447500A (en) 2000-08-29
NO331175B1 (no) 2011-10-24
SK288365B6 (sk) 2016-07-01
CN1346271A (zh) 2002-04-24
BRPI0017548B1 (pt) 2015-06-09
PL199802B1 (pl) 2008-10-31
JP2011037887A (ja) 2011-02-24
BRPI0017548B8 (pt) 2023-05-02
IL191581A0 (en) 2008-12-29
JP2002536414A (ja) 2002-10-29
PL350565A1 (en) 2002-12-16
NZ513204A (en) 2004-04-30
CN1597667A (zh) 2005-03-23
ID30552A (id) 2001-12-20
UA73932C2 (uk) 2005-10-17
NO20013882L (no) 2001-10-09
RU2262935C2 (ru) 2005-10-27
EE200900039A (et) 2011-02-15
TR200102314T2 (tr) 2002-01-21
EP1154774B1 (de) 2005-06-22
PT1154774E (pt) 2005-10-31
CA2674803C (en) 2012-10-09
CA2674803A1 (en) 2000-08-17
CA2362715A1 (en) 2000-08-17
SK288138B6 (sk) 2013-11-04
CZ20012889A3 (cs) 2001-11-14
US20060004017A1 (en) 2006-01-05
SK50292011A3 (en) 2002-01-07
EE05708B1 (et) 2014-04-15
EP2050744A1 (de) 2009-04-22
EE201100025A (et) 2011-08-15
CY1110979T1 (el) 2015-06-11
DE60020941D1 (de) 2005-07-28
SK500022013A3 (en) 2002-01-07
CA2362715C (en) 2010-10-19
NO20111095L (no) 2001-10-09
DK1553097T3 (da) 2010-12-13
NO321604B1 (no) 2006-06-12
KR20010102044A (ko) 2001-11-15
IS2807B (is) 2012-09-15
US8492560B2 (en) 2013-07-23
IL191580A0 (en) 2008-12-29
ZA200106340B (en) 2002-11-01
US7074800B1 (en) 2006-07-11
NO332895B1 (no) 2013-01-28
BR0008128A (pt) 2002-02-13
HU228964B1 (en) 2013-07-29
EE05345B1 (et) 2010-10-15
NZ530832A (en) 2005-05-27
EP1553097A1 (de) 2005-07-13
IL144745A (en) 2008-11-03
WO2000047212A1 (en) 2000-08-17
IL191580A (en) 2011-08-31
CZ303692B6 (cs) 2013-03-13
NO20052773D0 (no) 2005-06-08
DE60045047D1 (de) 2010-11-11
HUP0104964A3 (en) 2003-02-28
CN100360505C (zh) 2008-01-09
HUP0104964A2 (hu) 2002-04-29
SK288378B6 (sk) 2016-07-01
JP5710931B2 (ja) 2015-04-30
IS6022A (is) 2001-07-24
EP1154774A1 (de) 2001-11-21
NO20013882D0 (no) 2001-08-09
JP3893026B2 (ja) 2007-03-14
SI1553097T1 (sl) 2010-12-31
CZ306810B6 (cs) 2017-07-19
SI1154774T1 (en) 2005-10-31
ES2351699T3 (es) 2011-02-09
TR200500745T2 (tr) 2005-05-23

Similar Documents

Publication Publication Date Title
ATE482946T1 (de) Chinazolinderivate als angiogenesehemmer und zwischenprodukte dafür
US20200325130A1 (en) Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same
IL142359A0 (en) Quinazoline derivatives
KR100848197B1 (ko) 신호 전달 억제제 및 에포틸론 유도체를 포함하는 배합물
MY140507A (en) Quinazoline derivatives, pharmaceutical compositions containing them, processes for their preparation and their use in the production of an antiangiogenic and/or vascular permeability reducing effect

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1553097

Country of ref document: EP